Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
dc.contributor.author | Zrubka, Zsombor | |
dc.contributor.author | Gulácsi, László | |
dc.contributor.author | Brodszky, Valentin | |
dc.contributor.author | Rencz, Fanni | |
dc.contributor.author | Alten, Rieke | |
dc.contributor.author | Szekanecz, Zoltán | |
dc.contributor.author | Péntek, Márta | |
dc.date.accessioned | 2019-10-25T09:54:26Z | |
dc.date.available | 2019-10-25T09:54:26Z | |
dc.date.issued | 2019 | |
dc.date.oa | 2019-10-28 | |
dc.date.pasync | 2020-02-27T01:30:22Z | |
dc.date.updated | 2020-02-27T01:30:22Z | |
dc.description.corrector | LB | |
dc.identifier.citation | Expert Review of Pharmacoeconomics & Outcomes Research. -19 : 5 (2019), p. 537-549. -Expert Review of Pharmacoeconomics & Outcomes Research. - 1473-7167. - 1744-8379 | |
dc.identifier.doi | http://dx.doi.org/10.1080/14737167.2019.1647104 | |
dc.identifier.issn | 1473-7167 | |
dc.identifier.issn | 1744-8379 | |
dc.identifier.opac | http://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM081584 | |
dc.identifier.uri | http://hdl.handle.net/2437/275040 | |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/14737167.2019.1647104 | |
dc.language | eng | |
dc.rights.access | open access article | |
dc.subject.mab | Orvostudományok | |
dc.subject.mab | Klinikai orvostudományok | |
dc.title | Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis | |
dc.type | idegen nyelvű folyóiratközlemény külföldi lapban |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- FILE_UP_1_428 Zrubka SzZ Gulácsi infliximab costeff Expert Rev Pharmacoecon Outcome Res 2019.pdf
- Méret:
- 2.36 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- kiadói változat